John Paul de Koning
Director/Miembro de la Junta en ONWARD MEDICAL N.V. .
Origen de la red de primer grado John Paul de Koning.
| Entidad | Tipo de entidad | Industria | |
|---|---|---|---|
32
| Public Company | Biotechnology | 32 |
LSP Management Group BV
 LSP Management Group BV Investment ManagersFinance LSP Management Group BV (LSP) is an independent European venture capital firm which was founded by Martijn Kleijwegt, Frits van der Have and Tom Schwarz in 1998. Headquartered in Amsterdam, the firm provides financing to early- to mid-stage life science companies.
31
| Subsidiary | Investment Managers | 31 |
| Public Company | Miscellaneous Commercial Services | 23 | |
EQT Life Sciences Group BV
 EQT Life Sciences Group BV Investment ManagersFinance EQT Life Sciences Group BV (EQT Life Sciences) is a venture capital firm, a subsidiary of EQT AB founded in 2022 after the acquisition of LSP by EQT. The firm is headquartered in Amsterdam, the Netherlands.
22
| Subsidiary | Investment Managers | 22 |
eTheRNA immunotherapies NV
 eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium.
19
| Holding Company | Biotechnology | 19 |
15
| Public Company | Pharmaceuticals: Other | 15 |
| Extinct | Biotechnology | 14 | |
Varmx BV
 Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018.
13
| Holding Company | Biotechnology | 13 |
Xylocor Therapeutics, Inc.
 Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA.
12
| Holding Company | Pharmaceuticals: Major | 12 |
Skyline Diagnostics BV
 Skyline Diagnostics BV Electronic Equipment/InstrumentsElectronic Technology Skyline Diagnostics develops and commercializes diagnostic microarrays for oncology. These tests currently provide the healthcare professional diagnostic information using one comprehensive test and may be useful in the clinical management of patients with cancer. Skyline Diagnostics products are currently available research only tools in the United States. The development pipeline includes diagnostic tests for Acute Myeloid Leukemia, Multiple Myeloma, Acute Lymphatic Leukemia, and Brain tumors.
12
| Extinct | Electronic Equipment/Instruments | 12 |
Visus Therapeutics, Inc.
 Visus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation.
11
| Holding Company | Pharmaceuticals: Major | 11 |
Onward Medical SA
 Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland.
10
| Holding Company | Biotechnology | 10 |
Aelin Therapeutics NV
 Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert.
8
| Holding Company | Pharmaceuticals: Major | 8 |
Xilis, Inc.
 Xilis, Inc. Medical SpecialtiesHealth Technology Xilis, Inc. engages in the development of droplet-based microfluidics technology devices for precision cancer diagnostics and drug development. It offers Xilis platform. The company was founded by Xiling Shen and David Shu and is headquartered in Durham, NC.
8
| Holding Company | Medical Specialties | 8 |
MyCartis NV
 MyCartis NV BiotechnologyHealth Technology MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium.
5
| Holding Company | Biotechnology | 5 |
Innovative Biosensors, Inc.
 Innovative Biosensors, Inc. Medical SpecialtiesHealth Technology Innovative Biosensors, Inc. develops, manufactures and markets pathogen detection and diagnostic systems. Its systems comprises of biosensors that generate results at previously unseen levels of sensitivity and specificity. The firm also offers bioflash-dx, a diagnostics platform for the testing of infectious and other human diseases. The company was founded by Joe Hernandez in 2003 and is headquartered in Rockville, MD.
2
| Extinct | Medical Specialties | 2 |
BMEYE BV
 BMEYE BV Electronic Equipment/InstrumentsElectronic Technology BMEYE BV operates as a non-invasive cardiovascular monitoring company. The firm manufactures and distributes non-invasive technology, hemodynamic monitoring equipment and related medical devices. It offers finger arterial pressure and cardiac output technologies. The company was founded in April 2005 and is headquartered in Amsterdam, the Netherlands.
1
| Subsidiary | Electronic Equipment/Instruments | 1 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a John Paul de Koning a través de su red personal
| Empresa | Sector | Personas relacionadas | Puesto principal |
|---|---|---|---|
| ABLYNX | Biotechnology | Director/Board Member Director/Board Member Chairman Director/Board Member Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| Ghent University | College/University | Corporate Officer/Principal Corporate Officer/Principal Graduate Degree Doctorate Degree Doctorate Degree | |
| Katholieke Universiteit Leuven | College/University | Graduate Degree Graduate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
| University of Utrecht | College/University | Corporate Officer/Principal Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
| OCULIS HOLDING AG | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member Director/Board Member | |
| Vrije Universiteit Amsterdam | College/University | Graduate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
| Swiss Federal Institute of Technology | College/University | Graduate Degree Doctorate Degree Corporate Officer/Principal Doctorate Degree | |
Intrexon ActoBiotics NV
 Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
| University of Leiden | College/University | Graduate Degree Undergraduate Degree Graduate Degree Doctorate Degree | |
| Erasmus University Rotterdam | College/University | Graduate Degree Graduate Degree Doctorate Degree | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
| INSEAD | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
iSTAR Medical SA
 iSTAR Medical SA Medical SpecialtiesHealth Technology iSTAR Medical SA develops innovative ophthalmic implants. Its products include MINIject, STARflo and STAR Material. The company was founded by Michel Alvarez in 2011 and is headquartered in Wavre, Belgium. | Medical Specialties | Director/Board Member Director/Board Member Director/Board Member | |
Asceneuron SA
 Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Director/Board Member Chairman Chairman | |
deVGen NV
 deVGen NV BiotechnologyHealth Technology deVGen NV provides biotechnology services for the pharmaceutical and agrochemical industries. It innovates in crop protection research and environment induced stress tolerance for its own crops and provides technology to corporate partners. The firm produces and sells its hybrid seeds in field crops such as rice, sunflower, sorghum and pearl millet in the Indian subcontinent and Southeast Asia. The company was founded by Thierry Bogaert on September 10, 1997 and is headquartered in Ghent, Belgium. | Biotechnology | Director/Board Member Director of Finance/CFO Director/Board Member | |
FlandersBio vzw
 FlandersBio vzw Miscellaneous Commercial ServicesCommercial Services FlandersBio vzw is a life sciences cluster organization based in Flanders, Belgium. FlandersBio creates value by organizing networking and training activities, supporting internationalization, providing services, and building expertise. The Belgian company was founded by Jean Marie Stassen. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member | |
INKEF Capital BV
 INKEF Capital BV Investment ManagersFinance INKEF Capital BV is an Independent Venture Capital firm founded in 2010 by Frank R Landsberger. INKEF Capital BV is headquartered in Amsterdam. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Analyst | |
Duke University
 Duke University Other Consumer ServicesConsumer Services Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC. | College/University | Corporate Officer/Principal Undergraduate Degree Masters Business Admin | |
| CELYAD ONCOLOGY SA | Biotechnology | Chairman Director/Board Member Corporate Officer/Principal | |
| ATON | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member | |
| LUMOS DIAGNOSTICS HOLDINGS LIMITED | Medical Specialties | Director/Board Member Chief Executive Officer Chairman | |
| Radboud University Nijmegen | College/University | Undergraduate Degree Doctorate Degree General Counsel | |
| University of Twente | College/University | Corporate Officer/Principal Graduate Degree Graduate Degree | |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Biotechnology | Director/Board Member Chairman Director/Board Member | |
Ysios Capital Partners SGEIC SA
 Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor | |
| McGill University | College/University | Doctorate Degree Undergraduate Degree | |
| CURETIS N.V. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
| University of Michigan | College/University | Graduate Degree Doctorate Degree | |
reMYND NV
 reMYND NV Miscellaneous Commercial ServicesCommercial Services reMYND NV engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders. Its drug and development unit focuses on innovative, disease-modifying drugs for treating degenerative disorders. The company was founded by Fred Van Leuven, Stefaan Wera and Joris Winderickx in 2002 and is headquartered in Leuven, Belgium. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Lumos Diagnostics
 Lumos Diagnostics Medical SpecialtiesHealth Technology Lumos Diagnostics develops and provides diagnostic solutions. It offers assay development, reader development, and point-of-care diagnostic solutions. The company is headquartered in Carlsbad, CA. | Medical Specialties | Chief Executive Officer Chairman | |
Vlaams Instituut voor Biotechnologie - Flanders Institute
 Vlaams Instituut voor Biotechnologie - Flanders Institute Other Consumer ServicesConsumer Services Vlaams Instituut voor Biotechnologie - Flanders Institute operates as a non-profit organization, provides research and development services. It specializes in translating basic scientific results into pharmaceutical, agricultural and industrial applications. The company was founded on January 1, 1996 and is headquartered in Ghent, Belgium. | College/University | Director/Board Member Founder | |
Rigontec GmbH
 Rigontec GmbH Pharmaceuticals: MajorHealth Technology Rigontec GmbH provides RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The firm develops a compound stimulating the immune receptor retinoic acid-inducible gene. The company was founded by Annegret de Baey-Diepolder, Gunther Hartmann, Anna Schwickart, Marcel Renn, Christine Schuberth-Wagner and Veit Hornung in 2014 and is headquartered in Munich, Germany. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
LSP Advisory BV
 LSP Advisory BV Investment ManagersFinance Part of LSP Advisory Group BV, EQT Life Sciences is a healthcare investment firm based in Amsterdam, Netherlands. EQT Life Sciences has been connecting investors to inventors in the healthcare sector for over 30 years. The Dutch company has invested in close to two hundred private companies, raising billions of additional capital directed at supporting their R & D. EQT Life Sciences believes in fostering life and constant innovation in healthcare to achieve that goal. The company was founded in 1998, and Mark A. Wegter has been the CEO since then. Recently, EQT Life Sciences was acquired by EQT AB, one of the largest private equity firms in Europe, and among the top-ten private equity firms globally. | Investment Managers | Director/Board Member Chief Executive Officer | |
National Institutes of Health
 National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | General Government | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Egle Therapeutics SAS
 Egle Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Egle Therapeutics SAS is a biotech company based in Paris, France. Egle Therapeutics develops first-in-class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases. The French company leverages its translational-based target discovery platform to unveil novel therapeutic Treg targets and computationally designed immunocytokines acting as antagonists or as selective Treg-agonists. The company was founded in 2020 by Luc Boblet, a serial biotech entrepreneur, and Dr. Eliane Piaggio, a renowned immunologist. | Miscellaneous Commercial Services | Chief Executive Officer Director/Board Member | |
Neurotech Pharmaceuticals, Inc. (United States)
 Neurotech Pharmaceuticals, Inc. (United States) Pharmaceuticals: MajorHealth Technology Neurotech Pharmaceuticals, Inc. designs and develops therapeutic systems for retinal diseases. The company was founded in 1995 and is headquartered in Cumberland, RI. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
Pharvaris GmbH
 Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Pharmaceuticals: Major | Director/Board Member Founder | |
Vico Therapeutics BV
 Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Biotechnology | Director/Board Member Director/Board Member | |
| PHARVARIS N.V. | Pharmaceuticals: Major | Director/Board Member Founder | |
| University of Amsterdam | College/University | Undergraduate Degree Doctorate Degree | |
Curetis GmbH
 Curetis GmbH Medical SpecialtiesHealth Technology Curetis GmbH operates as a molecular diagnostics company which focuses on the development and commercialization of products for diagnosing severe infectious diseases. The firm offers diagnostic solutions for hospitals and large-scale laboratories. Its products include Unyvero L4 Lysator, Unyvero C8 Cockpit, Unyvero A50 Analyzer, and Unyvero Application Cartridges. The company was founded by Andreas Boos, Johannes Bacher, Gerd Lüdke, and Anne Thews in August 2007 and is headquartered in Holzgerlingen, Germany. | Medical Specialties | Director/Board Member Director/Board Member | |
Cardior Pharmaceuticals GmbH
 Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Cardior Pharmaceuticals GmbH develops, manufactures and wholesales drugs. It focuses on the discovery, development and clinical validation of noncoding RNA therapeutics targeting microRNAs as medicines for patients with various forms of heart failure. The company was founded by Sandor Batkai, Claudia Ulbrich, and Thomas Thum on July 21, 2016 and is headquartered in Hannover, Germany. | Pharmaceuticals: Major | Chairman Director/Board Member |
Estadísticas
Internacional
| Países Bajos | 18 |
| Bélgica | 11 |
| Estados Unidos | 8 |
| Suiza | 6 |
| Alemania | 6 |
Sectorial
| Health Technology | 23 |
| Consumer Services | 17 |
| Commercial Services | 6 |
| Finance | 6 |
| Health Services | 2 |
Operativa
| Director/Board Member | 538 |
| Corporate Officer/Principal | 138 |
| Chairman | 113 |
| Independent Dir/Board Member | 106 |
| Chief Executive Officer | 77 |
Las relaciones más conectadas
| Insiders | |
|---|---|
| Marijn Dekkers | 35 |
| Regina Hodits | 34 |
| Martijn Kleijwegt | 33 |
| Russell Greig | 31 |
| René Kuijten | 30 |
| Roel Bulthuis | 29 |
| Rudy Dekeyser | 29 |
| Joseph deBethizy | 29 |
| Patrick van Beneden | 28 |
| David Guyer | 27 |
| Lionel Carnot | 27 |
| Mark Iwicki | 26 |
| Anthony Adam Rosenberg | 23 |
| Prabhavathi Fernandes | 23 |
| Johannes G. C. P. Schikan | 22 |
- Bolsa de valores
- Insiders
- John Paul de Koning
- Conexiones Empresas